Loading
Chemokine Receptors and Signaling / Immune Cells in Cancer · Journal article
Frontiers in Immunology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes mechanistic and translational evidence regarding the CCL2–CCR2 signaling axis in lung cancer pathogenesis and metastasis. The authors conclude that although the axis shows biological promise and early translational potential as a therapeutic target, clinical validation remains limited and well-designed trials are needed to establish whether pathway modulation improves patient outcomes.
Journal article. Patients with primary lung cancer and pulmonary metastasis (reviewed literature; no direct study population).
CCL2–CCR2 signaling orchestrates recruitment of monocytes, tumor-associated macrophages, and myeloid-derived suppressor cells to establish an immune-permissive tumor microenvironment. The axis interacts with multiple oncogenic pathways including PI3K/Akt/mTOR, STAT3, NF-κB, and Toll-like receptor signaling to amplify pro-tumor inflammatory circuits. Context-dependent tumor-suppressive effects occur under specific biological conditions, such as M1 macrophage recruitment or enhanced antitumor immunity.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize the CCL2–CCR2 axis as an emerging biological target with mechanistic rationale but should note that clinical validation is currently insufficient to guide treatment decisions. Further well-designed clinical trials are required before pathway modulation can be recommended as standard practice.
A narrative review summarizing mechanistic evidence and preclinical/early translational data on the CCL2–CCR2 axis in lung cancer, without reporting original clinical trial results or definitive clinical outcomes.
Clinicians should recognize the CCL2–CCR2 axis as an emerging biological target with mechanistic rationale but should note that clinical validation is currently insufficient to guide treatment decisions. Further well-designed clinical trials are required before pathway modulation can be recommended as standard practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lung cancer remains the leading cause of cancer-related mortality worldwide, with metastasis, therapeutic resistance, and an immunosuppressive TME representing major barriers to successful treatment. Among the chemokine signaling networks implicated in these processes, the CCL2–CCR2 axis has emerged as an important regulator of tumor progression. By orchestrating the recruitment of monocytes, tumor-associated macrophages, myeloid-derived suppressor cells, and other stromal components, this pathway can establish an immune-permissive niche that supports angiogenesis, epithelial–mesenchymal transition, extracellular-matrix remodeling, metastatic dissemination, and resistance to chemotherapy, targeted therapies, and immunotherapy. Mechanistically, CCL2–CCR2 signaling interacts with key oncogenic pathways, including PI3K/Akt/mTOR, STAT3, NF-κB, Toll-like receptor signaling, and non-coding RNA-mediated networks, thereby amplifying pro-tumor inflammatory circuits within the lung TME. Although accumulating evidence indicates that the axis can exert context-dependent tumor-suppressive effects under specific biological conditions, such as promoting M1 macrophage recruitment or enhancing antitumor immunity in selected settings, its overall contribution in lung cancer appears predominantly tumor-promoting. This review comprehensively summarizes the molecular mechanisms governing CCL2–CCR2 signaling in primary lung cancer and in lung metastases. We further discuss emerging therapeutic strategies directed at this axis, including CCR2 antagonists, CCL2-neutralizing agents, engineered immune-cell approaches, and rational combinations with immune-checkpoint inhibitors and targeted therapies. Collectively, the current evidence provides a strong biological rationale and preliminary translational support for further investigation of the CCL2–CCR2 axis as a potential therapeutic target and exploratory biomarker in advanced lung cancer. However, clinical validation remains limited, and additional well-designed studies are required to determine whether modulation of this pathway can meaningfully improve patient outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.